[Efficacy and safety analysis of BCL-2 inhibitor in relapsed/refractory multiple myeloma with t (11;14) in a single center]

Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):146-149. doi: 10.3760/cma.j.issn.0253-2727.2022.02.010.

[Article in Chinese]

Authors

J Y Bi¹, L Wen¹, W B Duan¹, Y Liu¹, S S Wang¹, X J Huang¹, J Lu¹

Affiliation

¹ Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.

PMID: 35381676
PMCID: PMC8980639
DOI: 10.3760/cma.j.issn.0253-2727.2022.02.010

No abstract available

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Proto-Oncogene Proteins c-bcl-2

Substances

Antineoplastic Agents
Proto-Oncogene Proteins c-bcl-2
Dexamethasone